Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:KIN

Kindred Biosciences (KIN) Stock Price, News & Analysis

Kindred Biosciences logo

About Kindred Biosciences Stock (NASDAQ:KIN)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$9.24
$9.26
50-Day Range
$9.08
$9.25
52-Week Range
$3.46
$9.28
Volume
178,496 shs
Average Volume
840,890 shs
Market Capitalization
$420.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.

Remove Ads
Receive KIN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kindred Biosciences and its competitors with MarketBeat's FREE daily newsletter.

KIN Stock News Headlines

Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
Kindred Hospital East Greensboro
Japan's Sony terminates $10 bln Zee India merger
European Shares Edge Higher With ECB Meeting In The Spotlight
Earnings Optimism May Contribute To Continued Strength On Wall Street
See More Headlines

KIN Stock Analysis - Frequently Asked Questions

Kindred Biosciences, Inc. (NASDAQ:KIN) released its quarterly earnings results on Thursday, August, 5th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.04. The biopharmaceutical company earned $3.54 million during the quarter, compared to analyst estimates of $8.12 million. Kindred Biosciences had a negative trailing twelve-month return on equity of 54.19% and a negative net margin of 529.26%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Kindred Biosciences investors own include CorMedix (CRMD), Sorrento Therapeutics (SRNE), Micron Technology (MU), bluebird bio (BLUE), Novavax (NVAX), Bristol-Myers Squibb (BMY) and Meta Platforms (META).

Company Calendar

Last Earnings
8/05/2021
Today
4/11/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KIN
Fax
N/A
Employees
63
Year Founded
2013

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-21,800,000.00
Net Margins
-529.26%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$42.16 million
Price / Cash Flow
N/A
Book Value
$1.75 per share
Price / Book
5.29

Miscellaneous

Free Float
N/A
Market Cap
$420.52 million
Optionable
Optionable
Beta
1.30

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:KIN) was last updated on 4/11/2025 by MarketBeat.com Staff
From Our Partners